CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
Allogene Therapeutics Inc ALLO
$1.65
▼ -1.20%
($-0.02)
🔥 High Short Interest
Open
$1.69
Prev Close
$1.67
Day Range
$1.63 – $1.70
52W Range
$1.04 – $4.46
Market Cap
$570.06M
Beta
0.72
EPS (TTM)
$-0.49
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-10-11 |
| Shares Out. | 345,150,000 |
| Website | allogene.com/ ↗ |
| Phone | 16504572700 |
| Employees | 152 |
| Revenue | $4.6M |
| Gross Profit | $4.6M |
| Net Income | -$42.7M |
| Free Cash Flow | -$102.6M |
| Total Assets | $550.1M |
| Total Liabilities | $113.9M |
| Equity | $436.2M |
About Allogene Therapeutics Inc
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Allogene Therapeutics Inc is a publicly traded company under the ticker symbol ALLO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-09-01)